AstraZeneca and Pozen announced Monday that their pain reliever Vimovo for the treatment of arthritis had received positive agreement for approval by the 23 E.U. nations. Vimovo is a combination drug that reduces the risk of ulcers for frequent NSAID users.
Continue reading AstraZeneca, Pozen Clear E.U. Approval Hurdle for Arthritis Drug Vimovo
AstraZeneca, Pozen Clear E.U. Approval Hurdle for Arthritis Drug Vimovo originally appeared on DailyFinance on Mon, 11 Oct 2010 08:36:00.
Filed Under: Company News, Health Care, Astrazeneca, Stocks in the News